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Indolent systemic mastocytosis without skin
involvement vs. isolated bone marrow 
mastocytosis
We have read with great interest the paper by Zanotti
et al.1 about the description of “Isolated bone marrow
mastocytosis” (BMM) as an underestimated subvariant of
indolent systemic mastocytosis (ISM). This is a very inter-
esting paper in which an in depth study was performed
in a total of 99 consecutive ISM patients, diagnosed
either prospectively or retrospectively according to the
2008 WHO classification.2 However, the term used to
define the series of BMM might not be the most appro-
priate and may lead to confusion in the field.
In Zanotti’s report, after an in depth study, 46 of 84
patients (54.7%) who were referred because of unex-
plained/recurrent anaphylaxis or severe allergic reactions
to hymenoptera sting in the absence of typical skin
lesions (e.g. mastocytosis in the skin; MIS), were classi-
fied as BMM.
It is noteworthy that, indolent systemic mastocytosis
(ISM) in the absence of skin involvement (ISMs-) has
been previously recognized and described by several
groups. In fact, it was first recognized as a clinical entity
in 19913 and later, its clinical, biological, morphological,
immunophenotypical and KIT mutational characteristics
have been established in a large series of cases.4 In addi-
tion, Dr. Zanotti co-authored an elegant paper on
hymenoptera venom anaphylaxis and mastocytosis in
which patients lacking MIS but fulfilling criteria for SM
are classified as ISMs-.5 Detailed analysis of the reported
isolated BM mastocytosis cases1 shows that most likely
they correspond to the previously identified ISMs-
patients.
It should be emphasized that ISMs- clearly differs from
isolated BM mastocytosis in that the latter is an excep-
tional subcategory of ISM in the absence of both skin
lesions and MC-mediator related symptoms. In addition,
subjects with isolated BM mastocytosis typically show a
low MC burden2;6 and their diagnosis is occasionally
made during a BM study for pathological conditions
other than mastocytosis, due to its clinically silent behav-
ior (only 5 cases in our data base, Spanish Network on
Mastocytosis-REMA-, data not shown).
Conversely, ISMs- is a “true” systemic disease based on
the observation of systemic mast cell-mediator related
symptoms, difficult to explain in a BM restricted MC con-
dition. ISMs- is also frequently associated with osteo-
porosis and presence of multilineal KIT mutations is
detected in 3 out of 47 cases (6.7%) in our published
series4 and in a total of 4 out of 62 (6.4%) cases in the
updated REMA’s data base (REMA, unpublished data,
2011) which confers to these patients an increased prob-
ability for disease progression.7
The term isolated BM mastocytosis may lead the read-
ership not familiar with this disease to consider this con-
dition to be benign and of a localized nature, when in fact
it may be associated with life-threatening or even fatal
anaphylaxis with possibly around 5% of cases progress-
ing to aggressive disease. 
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